| Associated Funds |
Form D |
Role |
2011 - 2026 |
Raised |
AUM |
| OrbiMed Advisors LLC |
| OrbiMed Royalty & Credit Opportunities V Offshore LP |
021-529422
|
Executive Officer |
|
1,243.5 M
of 1,750.0 M |
788.6 M |
| OrbiMed Private Investments X LP |
021-559153
|
Executive Officer |
|
of 1,750.0 M |
1,572.9 M |
| OrbiMed Royalty & Credit Opportunities V LP |
021-529419
|
Executive Officer |
|
1,243.5 M
of 1,750.0 M |
1,128.1 M |
| OrbiMed Royalty & Credit Opportunities IV Offshore LP |
021-452404
|
Executive Officer |
|
344.5 M
of 500.0 M |
567.9 M |
| OrbiMed Asia Partners V LP |
021-443753
|
Director |
|
651.9 M
of 1,100.0 M |
947.9 M |
| OrbiMed Private Investments IX LP |
021-443751
|
Executive Officer |
|
1,849.5 M
of 1,900.0 M |
2,190.7 M |
| OrbiMed Royalty & Credit Opportunities IV LP |
021-443752
|
Executive Officer |
|
1,153.1 M
of 1,750.0 M |
1,417.7 M |
| OrbiMed Private Investments VIII LP |
021-374300
|
Executive Officer |
|
of 1,400.0 M |
1,683.2 M |
| OrbiMed Asia Partners IV LP |
021-247616
|
Executive Officer |
|
of 950.0 M |
1,352.1 M |
| OrbiMed Genesis Master Fund LP |
021-355430
|
Executive Officer |
|
353.3 M |
747.0 M |
| OrbiMed Royalty & Credit Opportunities III LP |
021-331673
|
Executive Officer |
|
889.8 M
of 1,200.0 M |
359.1 M |
| OrbiMed Private Investments VII LP |
021-304413
|
Executive Officer |
|
of 1,000.0 M |
1,130.8 M |
| OrbiMed Asia Partners III LP |
021-281414
|
Director |
|
540.0 M
of 540.0 M |
2,079.5 M |
| OrbiMed Israel Partners II LP |
021-253036
|
Executive Officer |
|
of 300.0 M |
298.5 M |
| OrbiMed Private Investments VI LP |
021-247616
|
Executive Officer |
|
of 950.0 M |
842.8 M |
| OrbiMed Royalty Opportunities II LP |
021-233267
|
Executive Officer |
|
900.0 M
of 900.0 M |
168.1 M |
| OrbiMed Global Healthcare Master Fund LP |
021-212193
|
Executive Officer |
|
17.1 M |
542.3 M |
| OrbiMed Private Investments V LP |
021-205773
|
Executive Officer |
|
699.5 M
of 700.0 M |
327.6 M |
| OrbiMed Asia Partners II LP |
021-201444
|
Director |
|
of 300.0 M |
108.2 M |
| OrbiMed Israel Partners Limited Partnership |
021-158558
|
Executive Officer |
|
190.4 M |
35.8 M |
| OrbiMed Partners II LP |
021-128771
|
Executive Officer |
|
1,779.5 M |
2,096.0 M |
| OrbiMed Private Investments IV LP |
021-137285
|
Executive Officer |
|
312.4 M
of 550.0 M |
78.8 M |
|
| Blossomhill Therapeutics Inc |
021-566357
|
Director |
|
84.2 M
of 84.2 M |
|
| Odyssey Therapeutics Inc |
021-565797
|
Director |
|
214.0 M
of 214.0 M |
|
| Star Therapeutics LLC |
021-559890
|
Director |
|
125.0 M
of 125.0 M |
|
| OrbiMed Asia Partners VI LP |
021-559156
|
Director |
|
of 850.0 M |
|
| Avenzo Therapeutics Inc |
021-556725
|
Director |
|
47.2 M
of 75.0 M |
|
| Lomond Therapeutics Holdings Inc |
021-529644
|
Director |
|
53.9 M
of 63.9 M |
|
| Garuda Therapeutics Inc |
021-528326
|
Director |
|
47.7 M |
|
| Belenos Biosciences Inc |
021-519049
|
Director |
|
48.0 M
of 55.0 M |
|
| Blossomhill Therapeutics Inc |
021-501240
|
Director |
|
88.6 M
of 100.0 M |
|
| Odyssey Therapeutics Inc |
021-499898
|
Director |
|
117.2 M
of 121.1 M |
|
| Adarx Pharmaceuticals Inc |
021-489353
|
Director |
|
200.0 M
of 200.0 M |
|
| Garuda Therapeutics Inc |
021-472601
|
Director |
|
62.1 M
of 62.9 M |
|
| Adarx Pharmaceuticals Inc |
021-471878
|
Director |
|
46.0 M
of 46.0 M |
|
| Arrivent Biopharma Inc |
021-469072
|
Director |
|
110.0 M
of 145.0 M |
|
| MBX Biosciences Inc |
021-465364
|
Director |
|
46.7 M
of 115.2 M |
|
| Odyssey Therapeutics Inc |
021-462964
|
Director |
|
168.0 M
of 174.9 M |
|
| Avenzo Therapeutics Inc |
021-460216
|
Director |
|
385.9 M
of 385.9 M |
|
| Alterome Therapeutics Inc |
021-429619
|
Director |
|
63.8 M
of 63.8 M |
|
| Odyssey Therapeutics Inc |
021-417003
|
Director |
|
91.6 M |
|
| Garuda Therapeutics Inc |
021-414560
|
Director |
|
48.1 M
of 71.8 M |
|
| Adarx Pharmaceuticals Inc |
021-410307
|
Director |
|
75.0 M
of 75.0 M |
|
| Kumquat Biosciences Inc |
021-409457
|
Director |
|
30.0 M
of 30.0 M |
|
| Adarx Pharmaceuticals Inc |
021-400299
|
Director |
|
15.5 M
of 15.5 M |
|
| Scribe Therapeutics Inc |
021-394477
|
Director |
|
100.0 M
of 100.0 M |
|
| Blossomhill Therapeutics Inc |
021-390805
|
Director |
|
71.0 M
of 71.0 M |
|
| Kumquat Biosciences Inc |
021-389617
|
Director |
|
50.0 M
of 50.0 M |
|
| Theseus Pharmaceuticals Inc |
021-388439
|
Director |
|
95.1 M
of 100.1 M |
|
| Adarx Pharmaceuticals Inc |
021-380734
|
Director |
|
6.0 M
of 6.0 M |
|
| Adarx Pharmaceuticals Inc |
021-372735
|
Director |
|
5.0 M
of 5.0 M |
|
| Kinnate Biopharma Inc |
021-372487
|
Director |
|
98.0 M
of 98.0 M |
|
| Compass Therapeutics Inc |
021-370115
|
Director |
|
60.5 M
of 70.0 M |
|
| Compass Therapeutics Inc |
021-370112
|
Director |
|
195.3 M
of 195.3 M |
|
| OrbiMed New Horizons Fund LP |
021-364898
|
Executive Officer |
|
61.6 M |
|
| Keros Therapeutics Inc |
021-362700
|
Director |
|
56.0 M
of 56.0 M |
|
| OrbiMed Asia Partners IV LP |
021-362067
|
Director |
|
486.9 M
of 750.0 M |
|
| Kinnate Biopharma Inc |
021-356223
|
Director |
|
74.5 M
of 74.5 M |
|
| Adicet Bio Inc |
021-350688
|
Director |
|
80.0 M
of 80.0 M |
|
| Passage Bio Inc |
021-348117
|
Director |
|
110.0 M
of 110.0 M |
|
| Kumquat Biosciences Inc |
021-344451
|
Director |
|
55.9 M
of 56.0 M |
|
| Springworks Therapeutics Inc |
021-337163
|
Director |
|
125.0 M
of 125.0 M |
|
| TP Therapeutics Inc |
021-324635
|
Director |
|
80.0 M
of 80.0 M |
|
| Theseus Pharmaceuticals Inc |
021-315789
|
Director |
|
22.1 M
of 22.1 M |
|
| Prevail Therapeutics Inc |
021-307751
|
Director |
|
57.0 M
of 65.0 M |
|
| Compass Therapeutics LLC |
021-302629
|
Director |
|
21.8 M
of 50.0 M |
|
| Arsanis Inc |
021-300012
|
Director |
|
20.0 M
of 20.0 M |
|
| Springworks Therapeutics LLC |
021-293982
|
Director |
|
12.8 M
of 103.0 M |
|
| Arsanis Inc |
021-286233
|
Director |
|
45.5 M
of 50.5 M |
|
| Selecta Biosciences Inc |
021-276281
|
Director |
|
5.0 M
of 5.0 M |
|
| Gemini Therapeutics Inc |
021-262383
|
Director |
|
2.0 M
of 2.0 M |
|
| Arsanis Inc |
021-262117
|
Director |
|
15.0 M
of 15.0 M |
|
| Adicet Bio Inc |
021-256078
|
Director |
|
11.3 M
of 13.9 M |
|
| Arsanis Inc |
021-254201
|
Director |
|
4.0 M
of 4.0 M |
|
| Alector LLC |
021-247718
|
Director |
|
32.3 M
of 32.3 M |
|
| Selecta Biosciences Inc |
021-247362
|
Director |
|
37.4 M
of 40.6 M |
|
| Intellia Therapeutics Inc |
021-247004
|
Director |
|
70.0 M
of 70.0 M |
|
| Adicet Bio Inc |
021-246441
|
Director |
|
25.4 M
of 43.3 M |
|
| Compass Therapeutics LLC |
021-242888
|
Director |
|
110.2 M
of 170.2 M |
|
| Selecta Biosciences Inc |
021-238498
|
Director |
|
5.9 M
of 7.5 M |
|
| Igenica Biotherapeutics Inc |
021-232823
|
Director |
|
5.1 M
of 6.2 M |
|
| Selecta Biosciences Inc |
021-223752
|
Director |
|
4.5 M
of 4.5 M |
|
| Selecta Biosciences Inc |
021-221143
|
Director |
|
6.0 M
of 6.0 M |
|
| OrbiMed Global Healthcare Fund LP |
021-220964
|
Executive Officer |
|
113.3 M |
|
| Selecta Biosciences Inc |
021-215195
|
Director |
|
5.3 M
of 10.0 M |
|
| Igenica Inc |
021-211523
|
Director |
|
7.0 M
of 14.1 M |
|
| Arsanis Inc |
021-201235
|
Director |
|
20.0 M
of 20.0 M |
|
| Singulex Inc |
021-197624
|
Director |
|
12.2 M
of 20.1 M |
|
| Igenica Inc |
021-185338
|
Director |
|
of 0.0 M |
|
| Aragon Pharmaceuticals Inc |
021-184610
|
Director |
|
50.0 M
of 50.0 M |
|
| Igenica Inc |
021-180189
|
Director |
|
20.3 M
of 33.3 M |
|
| Igenica Inc |
021-177577
|
Director |
|
of 0.0 M |
|
| Good Start Genetics Inc |
021-176051
|
Director |
|
10.0 M
of 14.0 M |
|
| Singulex Inc |
021-175008
|
Director |
|
15.3 M
of 21.3 M |
|
| Aragon Pharmaceuticals Inc |
021-174482
|
Director |
|
37.8 M
of 42.2 M |
|
| Acceleron Pharma Inc |
021-171126
|
Director |
|
30.5 M
of 30.5 M |
|
| Selecta Biosciences Inc |
021-168905
|
Director |
|
22.0 M
of 22.0 M |
|
| Selecta Biosciences Inc |
021-168906
|
Director |
|
3.5 M
of 26.0 M |
|
| Singulex Inc |
021-160167
|
Director |
|
9.7 M
of 10.1 M |
|
| Arsanis Inc |
021-154945
|
Director |
|
9.6 M
of 9.6 M |
|
| Arsanis Inc |
021-148139
|
Director |
|
0.4 M
of 0.4 M |
|
| Good Start Genetics Inc |
021-147866
|
Director |
|
18.2 M
of 18.2 M |
|
| Igenica Inc |
021-147477
|
Director |
|
of 0.1 M |
|
| Acceleron Pharma Inc |
021-143718
|
Director |
|
10.3 M
of 11.5 M |
|
| Igenica Inc |
021-141481
|
Director |
|
16.1 M
of 24.1 M |
|
| Aragon Pharmaceuticals Inc |
021-141104
|
Director |
|
12.0 M
of 22.0 M |
|
| Selecta Biosciences Inc |
021-125893
|
Director |
|
15.0 M
of 15.0 M |
|
| OrbiMed Partners LP |
021-91544-4N
|
Executive Officer |
|
128.1 M |
|
| Acceleron Pharma Inc |
021-63019
|
Director |
|
11.0 M
of 11.0 M |
|
| Amarin Corp PLC UK |
021-135720
|
Director |
|
70.0 M
of 70.0 M |
|
| Amnis Corp |
021-62596
|
Director |
|
0.9 M
of 1.5 M |
|
| Igenica Inc |
021-125537
|
Director |
|
of 0.0 M |
|
| Farallon Biosciences Inc |
021-131501
|
Director |
|
4.0 M
of 8.0 M |
|